/ Print /

PHARMACY BEST PRACTICES

Top considerations when determining whether to approve expensive drugsWeighing the ethics of approving expensive cancer drugs for patients facing terminal disease is a multifaceted endeavor. Here are some recommendations.
Creating a ‘robust’ specialty pharmacy networkThe correct approach to take when creating a specialty pharmacy network is a key issue for healthcare executives.
FDA approvals for specialty drugs to pick up in 2017Numerous specialty medications, generics, and biosimilars, are expected to be approved this year for cancer, inflammatory and autoimmune diseases, and other indications.
State medical marijuana laws continue to expandMedical marijuana’s therapeutic evidence base remains nascent and controversial but the regulatory landscape is evolving rapidly.
Payers strategize to manage opioid useHow managed care organizations manage opioid utilization and some of the limitations to those management strategies was a hot topic at the AMCP Annual Meeting.
Insulin treatment persistence varies among payersA study from Walgreens provides a benchmark of basal insulin treatment persistence across different payers in the United States.
Five things to know about Trump’s FDA lead pick GottliebOn March 10, the White House announced that President Donald Trump selected Scott Gottlieb, MD, who has worked for FDA in the past, as his choice to head the FDA. Here are five things managed healthcare executives should know about the pick.
Opinion: More industry-stakeholders play blame game for high drug costsOur policy analyst weighs in on a new drug industry PR campaign that attempts to shift the blame for high drug costs.
Five pharmacy regulations health execs must keep on their radars in 2017Here are five critical regulations that executives can begin to prepare for today.
What more transparency at the FDA means for health executivesResearchers create a set of recommendations for transparency at the agency in five principal areas.